| Heat shock protein 90-sheltered overexpression of insulin-like growth factor 1 receptor contributes to malignancy of thymic epithelial tumors. | |
| | |
MedLine Citation:
|
PMID: 21372220 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
PURPOSE: The underlying molecular mechanisms of thymic epithelial malignancies (TEMs) are poorly understood. Consequently, there is a lack of efficacious targeted therapies and patient prognosis remains dismal, particularly for advanced TEMs. We sought to investigate protumorigenic mechanism relevant to this understudied cancer. EXPERIMENTAL DESIGN: Recently established cell lines derived from thymic epithelial tumors were used as a model system. The anti-tumor activity of specific Hsp90 inhibitors was investigated by an analysis of cell viability, cell cycle, and apoptosis using MTT-assays and flow cytometry. Western blotting was used to investigate the altered expression of Hsp90 clients. Pharmacological inhibitors against select Hsp90 clients, as well as RNAi, were employed to test the relevance of each client independently. Tissue microarray analysis was performed to match the in vitro findings with observations obtained from patient-derived samples.RESULTS: Hsp90 inhibition significantly reduces cell viability of thymic carcinoma cells, induces cell cycle arrest and apoptosis, and blocks invasiveness. Hsp90 inhibition triggers the degradation of multiple oncogenic clients, e.g. IGF-1R, CDK4, and the inactivation of PI3K/Akt- and RAF/Erk-signaling. Mechanistically, the IGF/IGF-1R-signaling axis contributes to the establishment of the anti-apoptotic phenotype of thymic cancer cells. Finally, IGF-1R is overexpressed in advanced TEMs.CONCLUSIONS: We have unraveled a novel protumorigenic mechanism in TEMs, namely Hsp90-capacitated overexpression of IGF-1R, which confers apoptosis evasion in malignant thymic epithelial cells. Our data indicate that Hsp90 inhibition, which simultaneously blocks multiple cancer hallmarks, represents a therapeutic strategy in TEMs that may merit evaluation in clinical trials. |
| | |
Authors:
|
Marco Breinig; Philipp Mayer; Andreas Harjung; Benjamin Goeppert; Mona Malz; Roland Penzel; Olaf Neumann; Arndt Hartmann; Hendrik Dienemann; Giuseppe Giaccone; Peter Schirmacher; Michael André A Kern; Gabriela Chiosis; Ralf Joachim Rieker |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-3-3 |
Journal Detail:
|
Title: Clinical cancer research : an official journal of the American Association for Cancer Research Volume: - ISSN: 1078-0432 ISO Abbreviation: - Publication Date: 2011 Mar |
Date Detail:
|
Created Date: 2011-3-4 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9502500 Medline TA: Clin Cancer Res Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Department of General Pathology, University Hospital Heidelberg. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Aberrant methylation of the X-linked ribosomal S6 kinase RPS6KA6 (RSK4) in endometrial cancers.
Next Document: Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a ...